AMGEN: PHASE 3 OASIZ 303 STUDY OF DAZODALIBEP IN MODERATE-TO-SEVERE SYMPTOMATIC SJÖGREN’S DISEASE EXPECTED TO COMPLETE IN Q4 2026

Observed price moves

• AMGN+3.52%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.